Targeted therapy, involving HER2-targeted drugs like trastuzumab, pertuzumab, and pyrotinib, has significantly enhanced the prognosis of BC patients (Gabos et al., 2006; Li et al., 2017; Escrivá-de-Romaní et al., 2018; Collins et al., 2019). Here, ERBB2 is linked to breast cancer.